AddLife develops the organization to take advantage of future growth opportunities and strengthens the support to the portfolio companies by adding internally recruited resources with solid international operational experience.

"AddLife has grown significantly in recent years and acquired several major companies in Europe within multiple new segments. With this new and strengthened position, AddLife has gained access to many new growth opportunities and has also added new and highly competent international teams in the various companies. AddLife is now developing an organization for continued growth and to make the best use of future potential for organic growth and profitability improvement within the companies, collaborations between the companies, as well as new acquisitions" says Fredrik Dalborg, President and CEO of AddLife.

In the business area Medtech, AddLife adds a new position with responsibility for the companies within the Hospital business unit, which is filled by Luca Marenzi. Luca is today CEO of Biomedica, which was acquired in 2018 and was AddLife's first major acquisition outside the Nordics. Biomedica, which has a turnover of approximately SEK 700 million, has 13 subsidiaries in Central and Eastern Europe. Under Lucas' leadership, Biomedica has developed strongly, and profitability has improved significantly.

Peter Simonsbacka, who is currently the business area manager for the Labtech business area, assumes the new role of Chief Commercial Officer, with commercial responsibility for both the Labtech and Medtech business areas. Peter has a long and solid operational experience within both AddLife and Addtech and has successfully developed the business within Labtech and established the two business units Diagnostics and Biomedical and Research.

In recent years, Tara Kearney has led Healthcare 21 in its strong growth, both organically and through acquisitions. At the turn of the year, Tara left her operational role in Healthcare 21 after approximately 20 years in the company, the last few years as successful CEO. Healthcare 21 has a turnover of approximately SEK 1,700 million and is by far AddLife's largest company and a central part of the Medtech business area. Tara now takes the role of Senior Advisor with special responsibility for the portfolio companies Mediplast and MBA.

"With this strengthening of the organization, we add very valuable international operational competence and experience, enabling us to support our companies' continued development in an even better way. I am also very happy that we were able to implement this strengthening of the organization with internal competence, which is in line with our decentralized model and culture. Luca and Tara have extensive and very relevant experience of the growth phase that several of our companies are facing. Peter has a long and successful track record at AddLife as well as Addtech, developing companies and organization, and his extender responsibility ensures continuity in culture and processes" says Fredrik Dalborg.

"Based on a decision not related to the organizational changes, Martin Almgren has chosen to leave his role as business area manager for Medtech for new challenges outside of AddLife. I want to thank Martin for his valuable contributions and his many years within the group and wish him all the best in the future", comments Fredrik Dalborg.

Stockholm, February 13, 2023
AddLife AB (publ)

For more information, contact;
Fredrik Dalborg, President and CEO, +46 70 516 09 01
www.add.life

AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm. 
The information was submitted for publication at February 13, 2023 at 15:00 p.m. CET.